Navigation Links
Antidepressant Effectiveness Probably Overstated: Report
Date:1/16/2008

Researchers unclear on whether it's reluctance to submit or reluctance to publish negative findings

WEDNESDAY, Jan. 16 (HealthDay News) -- A systematic review of studies on antidepressants concludes that the positive effects of these drugs are probably overstated in the medical literature.

But it's not clear if the bias comes from a reluctance to submit negative manuscripts or decisions by journals not to publish them, or a combination of both, according to Oregon Health and Science University researchers, whose report is published in the Jan. 17 issue of the New England Journal of Medicine.

The researchers compared drug efficacy inferred from published studies with drug efficacy reported to a mandatory U.S. government registry of clinical trials, in which all results, including raw data, must be included.

Only 51 percent of studies in the U.S. Food and Drug Administration registry were considered by the agency to have positive results.

In the published medical literature, however, 94 percent of studies appeared positive.

The increase in the effectiveness of the drug ranged from 11 percent to 69 percent for individual drugs, and was 32 percent overall. The antidepressant Wellbutrin appeared to show a high level of bias.

The authors also noted that studies that were not positive were often published with a slant that made them seem positive.

"For the average patient, yes, these drugs are effective, just less effective than they appear," said study author Dr. Erick Turner, an assistant professor of psychiatry and pharmacology at Oregon Health Sciences University. "Don't be overly disappointed if you don't have an excellent response to the first antidepressant you try. You might have to try two or three, and you might need to add psychotherapy."

One expert hailed the finding.

"This is, in my opinion, an excellent paper and what it shows is really con
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Youth Suicide Warnings Are Slowing Antidepressant Sales
2. Antidepressants Help HIV-Infected Patients Stick to Treatment
3. Natural human hormone as the next antidepressant?
4. Study shows new strategy for developing antidepressants
5. Marijuana-like brain chemicals work as antidepressant
6. Antidepressants Boost GI Bleeding Risk
7. Antidepressants and painkillers - a dangerous combination
8. Genetic test announced for suicidal ideation in patients using antidepressant drugs
9. Genes Might Predispose Antidepressant Users to Suicidal Thoughts
10. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
11. Antidepressant as Good as Antipsychotics for Dementia
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Antidepressant Effectiveness Probably Overstated: Report
Antidepressant Effectiveness Probably Overstated: Report
Breaking Medicine News(10 mins):Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 2Health News:Harris Williams & Co. Advises Verathon Inc. in its Sale to Strategic Buyer Roper Industries 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 2Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 3Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 4Health News:Cohen Independent Research Group Issues a 'Buy' Rating With a Target Price of $2.48 for VHGI; 8K filed regarding $50,000,000.00 Treasure Gulch Gold Reserves 5Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 2Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 3Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 4Health News:Despite Early Uptake, Seasonal Flu Vaccination Rates are Similar to Last Year 5Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 2Health News:NCCN Guidelines for Non-Small Cell Lung Cancer Updated to Incorporate Maintenance Therapy 3Health News:AIUM gears up for 2010 Annual Convention in San Diego, Calif. 2
Breaking Medicine Technology:National Ergonomics Expo Sees Immediate 93% Exhibit Space Renewal for 2010; Equipois, Herman Miller, Neutral Posture, REDpoint International Win 2009 Attendees' Choice New Product Awards 2PRA International Hosts an Infectious Diseases Audio Conference 2PRA International Hosts an Infectious Diseases Audio Conference 3Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3Pioneer 28R 29 Surgical Technology Inc Receives Prestigious Spine Technology Awards 6722 1Pioneer 28R 29 Surgical Technology Inc Receives Prestigious Spine Technology Awards 6722 2Upsher Smith Announces Milestone in Development of CNS Strategy 6718 1Upsher Smith Announces Milestone in Development of CNS Strategy 6718 2Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 1Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 2Honeywell and Pro Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 6714 3
Other Medicine Technology:Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting 9California Stem Cell Agency Exaggerated Its Role in Funding Key Research 2